Document Detail

B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma.
MedLine Citation:
PMID:  22523221     Owner:  NLM     Status:  MEDLINE    
Despite advances in the understanding of diffuse large B-cell lymphoma (DLBCL) biology, only the clinically based International Prognostic Index (IPI) is used routinely for risk stratification at diagnosis. To find novel prognostic markers, we analyzed flow cytometric data from 229 diagnostic DLBCL samples using an automated multiparameter data analysis approach developed in our laboratory. By using the developed automated data analysis pipeline, we identified 71 of 229 cases as having more than 35% B cells with a high side scatter (SSC) profile, a parameter reflecting internal cellular complexity. This high SSC B-cell feature was associated with inferior overall and progression-free survival (P = .001 and P = .01, respectively) and remained a significant predictor of overall survival in multivariate Cox regression analysis (IPI, P = .001; high SSC, P = .004; rituximab, P = .53). This study suggests that high SSC among B cells may serve as a useful biomarker to identify patients with DLBCL at high risk for relapse. This is of particular interest because this biomarker is readily available in most clinical laboratories without significant alteration to existing routine diagnostic strategies or incurring additional costs.
Ali Bashashati; Nathalie A Johnson; Alireza Hadj Khodabakhshi; Matthew D Whiteside; Habil Zare; David W Scott; Kenneth Lo; Raphael Gottardo; Fiona S L Brinkman; Joseph M Connors; Graham W Slack; Randy D Gascoyne; Andrew P Weng; Ryan R Brinkman
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of clinical pathology     Volume:  137     ISSN:  1943-7722     ISO Abbreviation:  Am. J. Clin. Pathol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-23     Completed Date:  2012-06-22     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  0370470     Medline TA:  Am J Clin Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  805-14     Citation Subset:  AIM; IM    
Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
B-Lymphocytes / immunology,  pathology*
Cyclophosphamide / therapeutic use
Disease-Free Survival
Doxorubicin / therapeutic use
Flow Cytometry
Lymphoma, Large B-Cell, Diffuse / drug therapy,  immunology,  mortality*,  pathology*
Middle Aged
Prednisone / therapeutic use
Survival Rate
Treatment Outcome
Vincristine / therapeutic use
Grant Support
94132//Canadian Institutes of Health Research; EB008400/EB/NIBIB NIH HHS; R01 EB008400/EB/NIBIB NIH HHS
Reg. No./Substance:
0/Antibodies, Monoclonal, Murine-Derived; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A Dissection of the CD45/Side Scatter "Blast Gate".
Next Document:  Analysis of urine sediment for cytology and antigen expression in acute renal allograft rejection: a...